Transcatheter Valves At The Tipping Point

Although Edwards is the pioneer and market leader in TAVR, there is no shortage of competitors – in both the aortic and mitral valve segments – developing next-generation devices who would be happy with a fraction of this potential multibillion-dollar opportunity.

Edwards Lifesciences Corp. continues to compile clinical evidence for the safety and efficacy of its next-generation transcatheter aortic valve replacement (TAVR) devices and is expanding its global presence as competitors move closer to the US and non-US markets. Researchers presented late-breaking results from two trials at the 2013 American College of Cardiology (ACC) Annual Scientific Session last month in San Francisco that reflect favorably on both Edwards’ first-generation SAPIEN (the only US Food and Drug Administration-approved TAVR device, cleared in November 2011 for the treatment of inoperable patients, with the indication expanded to high-risk surgical patients in October 2012) and its second-generation, cobalt-chromium SAPIEN XT device with a new partially closed leaflet geometry, placed via the new lower-profile NovaFlex Delivery System. In addition, a first-in-human feasibility study has been published on the company's investigational, third-generation, balloon-expandable SAPIEN 3 device, delivered through a 14 French (14F) sheath, providing the first hints of that valve's potential for more accurate positioning and less post-procedure paravalvular (PV) regurgitation.

Meanwhile, the TAVR field continues to expand, with several next-generation devices expected to be launched in Europe this year and large competitors moving forward with US trials. At the same...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.